



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 8, 2025

Sean Bohen, M.D., Ph.D.
Chief Executive Officer and President
Olema Pharmaceuticals, Inc.
780 Brannan Street
San Francisco, California 94103

Re: Olema Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 3, 2025
File No. 333-284131

Dear Sean Bohen M.D., Ph.D.:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Julia R. Boesch